source
- Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earningsReplimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious…
- AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development modelAI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…